公开(公告)号：US20160331522A1

公开(公告)日：2016-11-17

申请号：US15111158

申请日：2015-01-16

Applicant: KOWA COMPANY, LTD.

Inventor： Kimiya Shimizu ,  Haruo Ishikawa

IPC: A61F2/16 ,  G02C7/02

CPC classification number: A61F2/1645 ,  G02C7/02 ,  G02C7/022 ,  G02C7/04 ,  G02C2202/06

Abstract: A tonic ophthalmic lens is described in which refractivity of the lens differs between a first direction on a plane perpendicular to an optical axis of the lens and a second direction which differs from the first direction on the plane. In addition, refractivity difference which is the difference between the refractivity in the first direction and the refractivity in the second direction varies depending on a position of the lens in a radial direction.

Abstract translation: 描述了一种矫正眼科镜片，其中透镜的折射率在垂直于透镜的光轴的平面上的第一方向与不同于平面上的第一方向的第二方向不同。 此外，作为第一方向的折射率与第二方向的折射率的差的折射率差根据透镜在径向的位置而变化。

公开(公告)号：US09365501B2

公开(公告)日：2016-06-14

申请号：US14397352

申请日：2013-04-30

Applicant: KOWA COMPANY, LTD.

Inventor： Masahiro Tamura ,  Takahide Oshita

IPC: C07C245/08 ,  A61L27/16 ,  C08F220/68 ,  C09B29/12 ,  C08F220/60 ,  A61L27/50 ,  C09B29/01 ,  C09B69/10

CPC classification number: C07C245/08 ,  A61F2/16 ,  A61F2002/16965 ,  A61L27/16 ,  A61L27/50 ,  A61L2430/16 ,  C08F220/00 ,  C08F220/60 ,  C08F220/68 ,  C09B29/0003 ,  C09B29/12 ,  C09B69/106 ,  C08L33/26

Abstract: A polymerizable UV-absorbing colorant monomer is provided, which is excellent in stability under alkaline conditions and which is available for a useful material polymer for an intraocular lens. A compound, which is represented by the following general formula (1), is used as a polymerizable UV-absorbing monomer available for a material polymer for an intraocular lens: (in the general formula (1), R1 is a hydrogen atom, a hydroxy group, a carboxy group, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a sulfonic acid group, or a benzyloxy group, R2 is a hydrogen atom, a hydroxy group, or an alkoxy group having 1 to 4 carbon atoms, and R3 is represented by the following formula (2)): (in the general formula (2), R4 is a hydrogen atom or a methyl group, and R5 is a single bond or an alkylene group having 1 to 4 carbon atoms which may have a substituent or substituents.)

Abstract translation: 提供了一种可聚合的UV吸收着色剂单体，其在碱性条件下的稳定性优异，并且可用于眼内透镜的有用材料聚合物。 使用由以下通式（1）表示的化合物作为可用于眼内透镜材料聚合物的可聚合的UV吸收单体：（在通式（1）中，R 1是氢原子， 羟基，羧基，碳原子数1〜8的烷基，碳原子数1〜8的烷氧基，磺酸基或苄氧基，R2是氢原子，羟基或烷氧基 具有1至4个碳原子的基团，R 3由下式（2）表示）：（在通式（2）中，R 4是氢原子或甲基，R 5是单键或亚烷基 具有1至4个可具有取代基的碳原子。）

公开(公告)号：US20140348913A1

公开(公告)日：2014-11-27

申请号：US14282449

申请日：2014-05-20

Applicant: KOWA COMPANY, LTD. ,  UMEKEN CO. LTD.

Inventor： Kazuhiro TANIE ,  Mikio Yokoyama ,  Toru Yuasa

IPC: A61K36/9066 ,  A61K9/20

CPC classification number: A61K36/9066 ,  A61K9/1652 ,  A61K9/167 ,  A61K36/39 ,  A61K36/899 ,  A61K2300/00

Abstract: Provided is a granular product that has reduced or suppressed bitterness even though comprising a bitter crude drug or an extract thereof, and that allows a pharmacological action of the bitter crude drug to be sufficiently expressed. The granular product comprises a bitter crude drug or an extract thereof in each of the inner part and outer layer of the granular product.

Abstract translation: 本发明提供即使含有苦味的生药或其提取物也能降低或抑制苦味，并能够充分表达苦味生药的药理作用的颗粒状产品。 颗粒状产品在颗粒状产品的内部和外层的每一个中包含苦味的生物药物或其提取物。

公开(公告)号：US20140342469A1

公开(公告)日：2014-11-20

申请号：US14357550

申请日：2012-11-08

Applicant: KOWA COMPANY, LTD.

Inventor： Katsumi Yabusaki

IPC: G01N21/64

CPC classification number: G01N21/6486 ,  G01N21/6428 ,  G01N21/82 ,  G01N33/579

Abstract: A method for measuring a specific physiologically active substance of biological origin includes preparing a mixed solution of an AL reagent and a sample containing the physiologically active substance and detecting the aggregation or gelatinization of a protein in the mixed solution while agitating the mixed solution, thereby detecting the physiologically active substance or measuring the concentration of the physiologically active substance in the sample. A predetermined fluorescence emission is imparted to a substance involved in the aggregation or gelatinization in the sample to be measured and/or the AL reagent, and the fluorescence emitted from the substance involved in the aggregation or gelatinization is measured or observed in the mixed solution. In this manner, the aggregation or gelatinization in the mixed solution can be detected.

Abstract translation: 用于测定生物来源的特定生理活性物质的方法包括制备AL试剂和含有生理活性物质的样品的混合溶液，并在搅拌混合溶液的同时检测混合溶液中蛋白质的聚集或凝胶化，从而检测 生理活性物质或测量样品中生理活性物质的浓度。 对被测定样品和/或AL试剂的凝集或凝胶化所涉及的物质赋予规定的荧光发射，并且在混合溶液中测定或观察从涉及聚集或凝胶化的物质发射的荧光。 以这种方式，可以检测混合溶液中的聚集或凝胶化。

公开(公告)号：US20140330022A1

公开(公告)日：2014-11-06

申请号：US14370144

申请日：2013-01-04

Applicant: KOWA COMPANY, LTD.

Inventor： Hideo Yoshida ,  Shinsuke Itoh

IPC: A61K31/4704

CPC classification number: A61K31/4704 ,  C07D215/22

Abstract: Provided is compound for improving blood flow at sites of impaired circulation in the extremities, through promoting development of collateral blood circulation without angiogenesis; also provided is a therapeutic agent for sensitivity to cold or cold sensation, in which the active ingredient is a compound for improving blood flow at sites of impaired circulation in the extremities. A collateral blood flow development promoter, in which the active ingredient is (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate thereof.

Abstract translation: 提供了通过促进血管生成的侧支血液循环的发展来改善四肢受损循环部位的血流量的化合物; 还提供了对冷或感觉敏感的治疗剂，其中活性成分是用于改善四肢中循环受损部位的血液流动的化合物。 其中活性成分为（ - ） - 6- [3- [3-环丙基-3 - [（1R，2R）-2-羟基环己基]脲基]丙氧基] -2（1H） - 喹啉酮或其盐，或其溶剂合物。

公开(公告)号：US20140024055A1

公开(公告)日：2014-01-23

申请号：US14045478

申请日：2013-10-03

Applicant: KEIKO YOSHIMOTO ,  TSUTOMU TAKEUCHI ,  KOWA COMPANY, LTD.

Inventor： Tsutomu Takeuchi ,  Keiko Yoshimoto

IPC: G01N33/68

CPC classification number: G01N33/68 ,  A61K2039/505 ,  C07K14/70575 ,  C07K16/241 ,  G01N33/564 ,  G01N33/74 ,  G01N2500/00

Abstract: An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) as represented by SEQ ID: NO. 1 corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above antibody; a medicinal composition containing the antibody; utilization of the antibody; and a method of screening an inhibitory effect or an activating effect on BAFF with the use of the antibody.

Abstract translation: 具有如SEQ ID NO：1所示的具有氨基酸序列AVQGPEETVT QDC（以单字母​​氨基酸编码表示）的肽的抗体。 1对应于人BAFF（属于TNF家族的B细胞激活因子）中的134位至146位的蛋白质，其优选为单克隆抗体; 制备上述抗体的方法; 含有该抗体的药物组合物; 抗体的利用; 以及使用抗体筛选对BAFF的抑制作用或活化作用的方法。

公开(公告)号：US20130183763A1

公开(公告)日：2013-07-18

申请号：US13746487

申请日：2013-01-22

Applicant: Toru Obata ,  KOWA COMPANY LTD.

Inventor： Toru OBATA ,  Yoshiaki SHIRASAWA

IPC: G01N21/51

CPC classification number: G01N21/51 ,  G01N15/0205 ,  G01N21/532 ,  G01N21/82 ,  G01N2015/003 ,  Y10T436/143333

Abstract: In a measuring apparatus for measuring a target substance in a sample cell via a gelation reaction, a sample cell houses a specimen containing the substance to be measured, and a solution containing a gelating reagent is irradiated with a laser beam. The solution in the sample cell is stirred to generate minute and uniform gel particles, which are caused to pass through the laser beam. Scattered light from the gel particles generated in the sample cell is detected by a photodiode array, and the scattered-light intensity of the generated gel particles or the diameter and the number thereof is measured on time series by a computer on the basis of a scattered-light detection output of the photodiode array.

Abstract translation: 在用于通过凝胶化反应测量样品池中的目标物质的测量装置中，样品池容纳含有待测物质的样品，并且用激光束照射含有凝胶剂的溶液。 将样品池中的溶液搅拌以产生微小均匀的凝胶颗粒，使其通过激光束。 通过光电二极管阵列检测来自样品池中产生的凝胶颗粒的散射光，并且通过计算机基于散射来测量产生的凝胶颗粒的散射光强度或其直径和数量。 光电二极管阵列的光检测输出。

公开(公告)号：US20040132635A1

公开(公告)日：2004-07-08

申请号：US10673380

申请日：2003-09-30

Applicant: KOWA COMPANY, LTD.

Inventor： Takashi Nakagawa ,  Hiroyuki Ishiwata ,  Toshiaki Takizawa ,  Toru Kanke ,  Yasushi Wada ,  Junichi Kawagoe

IPC: A61K031/00

CPC classification number: A61K38/4846 ,  A61K38/08 ,  A61K38/482 ,  A61K38/4826 ,  G01N33/6893 ,  G01N2500/00 ,  G01N2800/347

Abstract: The present invention relates to a composition for prevention and treatment of kidney diseases comprising one or more effective component(s) of a PAR-2 activating agent which is able to activate PAR-2 and a pharmaceutically acceptable carrier. The present invention further relates to a method for prevention and treatment of kidney diseases comprising administration of a composition for prevention and treatment of kidney diseases containing a PAR-2 activating agent which is able to activate PAR-2 to patients suffering from kidney diseases, and also relates to the use of a PAR-2 activating agent which is able to activate PAR-2 for the manufacture of a composition for prevention and treatment of kidney diseases. The present invention furthermore relates to a method for screening an effective ingredient for prevention and treatment of kidney diseases comprising screening of the activating action of the test substance to PAR-2.

Abstract translation: 本发明涉及一种用于预防和治疗肾脏疾病的组合物，其包含能够激活PAR-2的PAR-2活化剂的一种或多种有效成分和药学上可接受的载体。 本发明还涉及一种用于预防和治疗肾脏疾病的方法，其包括给予含有能够使患有肾脏疾病的患者PAR-2的PAR-2激活剂的肾脏疾病的预防和治疗组合物，以及 还涉及能够激活PAR-2用于制备用于预防和治疗肾脏疾病的组合物的PAR-2活化剂的用途。 本发明还涉及筛选用于预防和治疗肾脏疾病的有效成分的方法，其包括将测试物质的活化作用筛选到PAR-2。

公开(公告)号：US20030087928A1

公开(公告)日：2003-05-08

申请号：US10079641

申请日：2002-02-20

Applicant: Kowa Company, Ltd., Japan

Inventor： Kimiyuki Shibuya ,  Katsumi Kawamine ,  Yukihiro Sato ,  Toshiyuki Edano ,  Mitsuteru Hirata ,  Chiyoka Ozaki

IPC: C07D471/02 ,  C07D498/02 ,  C07D491/02 ,  A61K031/4745

CPC classification number: C07D263/58 ,  C07D233/84 ,  C07D235/28 ,  C07D263/60 ,  C07D277/74 ,  C07D413/04 ,  C07D413/12 ,  C07D471/04

Abstract: The invention relates to novel anilide compounds represented by the following formula IV: 1 as that formula is further defined herein. The inventive compounds are useful in the form of a pharmaceutical composition, specifically as an acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.

Abstract translation: 本发明涉及由下式IV表示的新的酰苯胺化合物：该式在本文进一步定义。 本发明的化合物可以以药物组合物的形式使用，特别是酰基辅酶A胆固醇酰基转移酶（ACAT）抑制剂。

公开(公告)号：US20250057418A1

公开(公告)日：2025-02-20

申请号：US18723385

申请日：2022-12-22

Applicant: Kowa Company, Ltd.

Inventor： Atsushi KAKUUCHI

IPC: A61B3/135

Abstract: To provide a medical examination device having a plurality of irradiation lights that can be independently controlled while achieving downsizing, the medical examination device includes: an observation optical system that observes a subject; an illumination optical system including a slit light generation unit that generates slit light, a first light generation unit that generates first light different from the slit light, and an exterior in which a slit light irradiation port that emits the slit light and a first light irradiation port that emits the first light are formed at different positions; and a control unit that controls the illumination optical system. The first light generation unit includes a first light source disposed at a position where the first light can be emitted from the first light irradiation port.